Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Interest & Investment Income came in at $2.1 million in Q1 2026, down 9.08% YoY from $2.3 million in Q1 2025, and down 13.96% on a QoQ basis from $2.4 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 10 years of Interest & Investment Income data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Interest & Investment Income fell 9.08% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (down 24.65% YoY) and the FY2025 annual result came in at $9.4 million, down 36.07% from the prior year.
- Interest & Investment Income slipped to $2.1 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $4.3 million in Q4 2023 to a low of $2.1 million in Q3 2025.
- A 4-year average of $2.9 million and a median of $2.6 million in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2025 — Interest & Investment Income tumbled 39.83% — and 2026, when it slipped 9.08%.
- Tracing ENTA's Interest & Investment Income over 4 years: stood at $4.3 million in 2023, then sank by 34.88% to $2.8 million in 2024, then decreased by 13.47% to $2.4 million in 2025, then fell by 13.96% to $2.1 million in 2026.
- The last three Interest & Investment Income figures came in at $2.1 million (Q1 2026), $2.4 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.90 Mn |
| Mar 31, 2026 | 2.08 Mn |
| Dec 31, 2025 | 2.42 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 2.29 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Dec 31, 2017 | 928,000.00 |
| Sep 30, 2017 | 783,000.00 |
| Jun 30, 2017 | 628,000.00 |
| Mar 31, 2017 | 572,000.00 |
| Dec 31, 2016 | 549,000.00 |
| Sep 30, 2016 | 497,000.00 |
| Jun 30, 2016 | 474,000.00 |
| Mar 31, 2016 | 408,000.00 |
| Dec 31, 2015 | 356,000.00 |